| 摘要 |
The present invention relates to compounds of formula IAwherein Ris hydrogen or phenyl, optionally comprising as substituent halogen, CN or Calkoxy group or Calkoxy group substituted by halogen; Ris hydrogen or Calkyl; Ris hydrogen or Calkyl or is phenyl optionally comprising one or more substituents, selected from the following: halogen, cyano group or Calkoxy group substituted by halogen, or is pyridinyl, optionally comprising as substituent halogen or Calkyl substituted by halogen, or is pyrimidinyl, optionally comprising as substituent Calkyl substituted by halogen, or is pyrazinyl, optionally comprising as substituent halogen, cyano group or Calkyl substituted by halogen; Z is a bond, -CH- or -O-; or to compounds of formula IBwherein Ris hydrogen or phenyl, optionally comprising as substituent halogen, CN or Calkoxy group or Calkoxy group substituted by halogen; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl or phenyl; Z is a bond, -CH- or -O-; or to pharmaceutically acceptable acid addition salts thereof. It has been found that the compounds of formulas IA and IB have a good affinity to the trace amine associated receptors TAAR1. The compounds may be used for the treatment of psychotic disorders, neurological diseases, neurodegenerative disorders, metabolic disorders and cardiovascular diseases. |
